Schizophrenia and drug delivery systems

Journal of Drug Targeting

Volumn 8, Issue 2, 2000, Pages 107-117

  Cheng, Yu Hui ^a   Illum, L ^a,b   Davis, S S ^a,b  

^a Drug Delivery and Clinical Research Centre Ltd   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Antipsychotic; Drug delivery system; Schizophrenia

Indexed keywords

AMISULPRIDE; BENPERIDOL; BROMPERIDOL; CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; DROPERIDOL; FLUPENTIXOL; FLUPHENAZINE; FLUSPIRILENE; HALOPERIDOL; LEVOMEPROMAZINE; LOXAPINE; MESORIDAZINE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; OXYPERTINE; PERPHENAZINE; PIMOZIDE; PROCHLORPERAZINE; PROMAZINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; SULPIRIDE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; TRIFLUPERIDOL;

AKATHISIA; CONSTIPATION; CONTROLLED RELEASE FORMULATION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; MUSCLE RIGIDITY; MUSCLE SPASM; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; TABLET; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 0034085202     PISSN: 1061186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/10611860008996856     Document Type: Review

References (36)

1. Anderson, J.M. and Shive, M.S. (1997) Biodegradation and biocompatibility of PLA and PLGA microspheres, Advanced Drug Delivery Reviews, 28, 5-24.
2. Baldessarini, R.J. (1996) Drug and the treatment of psychiatric disorders: Psychosis and anxiety, in: Hardman, J.G., Limbird, L.E., Molinoff, P.B., Ruddon, R.W. and Gilman, A.G. (Eds.), Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edn. (McGraw-Hill Companies, Inc., New York), pp. 399-430.
3. Banker, G.B. and Rhodes, C.T. (1996) Drug products: A view to the future, in: Banker, G.S. and Rhodes, C.T. (Eds.), Modern Pharmaceutics, Third edn., Revised and Expanded (Marcel Dekker, Inc., New York), pp. 887-906.
4. Batey, S.R. (1989) Schizophrenic disorders, in: DiPiro, J.T., Talbert, R.L., Hayes, P.E., Yee, G.C. and Posey, L.M. (Eds.), Pharmacotherapy, A Pathophysiologic Approach (Elsevier Science Publishing Co., Inc., New York), pp. 748-746.
5. Beck, L.R., Cowsar, D.R., Lewis, J.W., Gibson, D.H. and Flowers, C.E. (1979) New long-acting injectable microcapsule contraceptive systems, Am. J. Obstet. Gynecol., 135, 419.
6. Beck, L.R., Flowers, C.E., Pope, V.Z., Wilborn, W.H. and Tice, T.R. (1983a) Clinical evaluation of an improved injectable microcapsule contraceptive system, Am. J. Obstet. Gynecol., 147, 815.
7. Beck, L.R., Pope, V.Z., Flowers, C.E., Cowsar, D.R., Tice, T.R., Lewis, D.H., Dunn, R.L., Moore, A.R. and Gilly, R.M. (1983b) Poly(DL-lactic-co-glycolide)/norethisterone microcapsules: An injectable biodegradable contraceptive, Bio. Reprod., 28, 186.
8. Beck, L.R., Pope, V.Z., Cowsar, D.R., Lewis, D.H. and Tice, T.R. (1980) Evaluation of a new three-month injectable contraceptive microsphere system in primate (baboon), Contracept. Deliv. Syst., 1, 79.
9. Beck, L.R., Pope, V.Z., Tice, T.R. and Gilly, R.M. (1985) Long-acting injectable microsphere formulation for the parenteral administration of levonorgestrel, Adv. Contracept., 1, 119.
10. Beck, L.R., Ramos, R.A., Flowers, C.E., Lopez, G.Z., Lewis, D.H. and Cowsar, D.R. (1981) Clinical evaluation of injectable microcapsule contraceptive systems, Am. J. Obstet. Gynecol., 140, 799.
11. Brannon-Peppas, L. (1995) Recent advances on the use of biodegradable microspheres and nanoparticles in controlled drug delivery, Int. J. Pharm., 116, 1-9.
12. British Medical Association and the Royal Pharmaceutical Society of Great Britain (Eds.) (1990) British National Formulary, Number 37, March 1999 (The Pharmaceutical Press, Oxon, UK), pp. 167-178.
13. Cheng, Y.-H., Illum, L. and Davis, S.S. (1998) A poly(D,L-lactide-co-glycolide) microsphere depot system for delivery of haloperidol, J. Controlled Release, 55, 203-212.
14. Chustecka, Z. (1997) Throwing a life-line to schizophrenia patient, Scrip Magazine, December, 34-38.
15. Davis, J.M., Janicak, P.G., Singla, A. and Sharma, R.P. (1993) Maintenance medication, in: T. Barnes (Ed.), Antipsychotic Drugs and their Side-Effects (Academic Press Limited, London), pp. 183-203.
16. Davis, S.S. and Illum, L. (1989) Microspheres as drug carriers, in: Roerdink, F.H.D. and Kroon, A.M. (Eds.), Drug Carrier Systems (John Wiley & Sons Ltd.), pp. 131-153.
17. Jalil, R. (1990) Biodegradable poly(lactic acid) and poly(lactide-co-glycolide) polymers in sustained drug delivery, Drug Develop. Industry Pharm., 16, 2353-2367.
18. Janssen-Cilag Ltd. (1996) HALDOL* DECANOATE, in: ABPI Compendium of Data Sheets and Summaries of Product Characteristics (Datapharm Publications Limited, London), pp. 450-451.
19. Johnson, D.A.W. (1993) Depot neuroleptics, in: Barnes T. (Ed.), Antipsychotic Drugs and Their Side-Effects (Academic Press Ltd., London), pp. 205-212.
20. Kendler, K.S. (1986) Genetic of schizophrenia, in: Francis, A.J. and Hales, R.E. (Eds.), Psychiatry Update: American Psychiatric Association Annual Review (Washington DC, American Psychiatric Press), Vol. 5, pp. 25-47.
21. Kino, S., Osajima, T. and Mizuta, H. (1994) Sustained-release microspheres containing antipsychotic and process for producing the same, International Patent Application, WO 94/10982.
22. Lewis, D.H. (1990) Controlled release of bioactive agents from lactide/glycolide polymers, in: Chasin, M. and Langer, R. (Eds.), Biodegradable Polymers as Drug Delivery System (Marcel Dekker, Inc., New York), pp. 1-41.
23. Maidment, I. (1998) Atypical antipsychotics - how not to market a medicine, The Pharmaceutical Journal, 261, 778.
24. Mensens, J.L., Rickey, M.E. and Atkins, T.J. (1995) Microparticle formulation of piperidinyl-1,2-benzazole compounds - in polymeric matrix providing controlled release, especially used as antipsychotic agent, International Patent Application, WO 95/13814.
25. Mir, S. and Taylor, D. (1998) Schizophrenia, The Pharmaceutical Journal, 261, 55-58.
26. Okada, H. and Toguchi, H. (1995) Biodegradable microspheres in drug delivery, Critic Rev. Therapeutic Drug Carrier System, 12, 1-99.
27. Products (July 1997) Expanding the market for new antipsychotics, SCRIP, No. 2248, 15.
28. Pufulete, M. (1997) The voices within, Chemistry in Britain, 33, 31-35.
29. Ramtoola, Z., Corrigan, O.I. and Barrett, C.J. (1992) Release kinetics of fluphenazine from biodegradable microspheres, J. Microencapsulation, 9, 415-423.
30. Reynolds, J.E.F., Parfitt, K., Parsons, A.V. and Sweetman, S.C. (Eds.) (1996), MARTINDALE The Extra Pharmacopoeia, 31st Edn. (Royal Pharmaceutical Society. London, UK), pp. 714-715.
31. Robinson, J.R. (1997) Controlled drug delivery, in: K. Park (Ed.), Controlled Drug Delivery, Challenges and Strategies (American Chemical Society, Washington, DC), pp. 1-7.
32. Rogers, H.J., Spector, R.G. and Trounce, J.R. (1981) A Textbook of Clinical Pharmacology (Hodder and Stoughton, London), pp. 193-247.
33. Sinkula, A.A. (1985) Sustained drug action accomplished by the prodrug approach, in: Bundgaard, H. (Ed.), Design of Prodrug (Elsevier, Amsterdam. The Netherlands), pp. 157-176.
34. Stimmel, G.L. (1992) Schizophrenia, in: Herfindal, E.T., Gourley, D.R. and Hart, L.L. (Eds.), Clinical Pharmacy and Therapeutics, Fifth edn. (Williams & Wikins, Baltimore), pp. 944-956.
35. Suzuki, K. and Price, J.C. (1985) Microencapsulation and dissolution properties of a neuroleptic in a biodegradable polymer poly(d,l-lactide), J. Pharm. Sci., 74, 21-24.
36. Whateley, T.L. (1993) Biodegradable microspheres for controlled drug delivery, in: Karsa, D.R. and Stephenson, R.A. (Eds.) Encapsulation and Controlled Release (The Royal Society of Chemistry), pp. 52-65.